AbbVie has reported Q1 2026 revenue of USD 15.0 billion, a 10.3% increase at constant exchange rates. The immunology franchise, led by Skyrizi (risankizumab) and Rinvoq (upadacitinib), continued its strong growth, increasing 14.3% to USD 7.3 billion. The combined sales of the two drugs reached USD 6.6 billion for the quarter, positioning Skyrizi to potentially reach USD 20 billion in annual sales. The neuroscience segment also saw robust growth of 24.3% to USD 2.9 billion.

The oncology segment declined 3% to USD 1.6 billion, though the BCL-2 inhibitor Venclexta (venetoclax) grew 9.7% to USD 770 million. The FRα antibody-drug conjugate (ADC) Elahere (mirvetuximab soravtansine) grew 8.3% to USD 198 million. AbbVie highlighted upcoming 2026 milestones, including potential regulatory approval for a vitiligo indication for Rinvoq, approval for its CD123-targeted ADC pivekimab sunirine, and Phase III data for its first-in-class autoimmune bispecific antibody (BsAb), lutikizumab.

According to PharmCube's NextBiopharm® database, pivekimab sunirine has performed favourably in all clinical studies so far. Click here to request a free trial for NextBiopharm®.